Czerepak becomes new CFO of Vaxin
Czerepak has more than 20 years of experience in biotech, pharmaceutical and venture capital industries financing. Her duties as the new CFO of Vaxin are to supervise merger and acquisition activities, encourage interactions between Vaxin and the investor community, and enhance Vaxin’s overall financial organization.
"Elizabeth's appointment represents a significant milestone for Vaxin," CEO and President Bill Enright said. "Our recent acquisition of Immune Targeting Systems, coupled with a $16 million funding infusion, has propelled the company into a new growth stage. It is critical now that we have an executive dedicated to supporting the growth with prudent financial management. Elizabeth's experience as a venture capitalist, coupled with her executive-level finance, business development and operational expertise in our industry, makes her an ideal fit for this important role."
In previous positions, Czerepak has been a leader of public and private initiatives. She has raised millions of dollars for private financings and initial public offerings. She has gained $537 million and $364 million worth of acquisitions of portfolio companies.
"This is an exciting time to join Vaxin as CFO," Czerepak said. "The company's two-vaccine platform strategy makes it uniquely positioned to address the emerging public health and biodefense challenges that the nation and the world will face in the coming years."
Czerepak attended Marshall University, where she graduated magna cum laude with a bachelor of arts, and then earned her MBA from Rutgers University.